Filter posts

FOX Business: BIO CEO Jim Greenwood Discusses State of the Industry

BIO President and CEO Jim Greenwood recently appeared on Fox Business Risk & Reward with …

The Perfect Close

With a fast and furious finish, yesterday, March 2nd, the Nasdaq Composite (IXIC) closed at …

Nasdaq Social Bell: Twitter Strategies For Biotechs

Last week at the BIO CEO & Investor Conference in New York City, I had …

Prosensa's IPO and the Value of the BIO Investor Forum

Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the discovery and development of …

How does the NBI perform in the last quarter of the year?

Does the NASDAQ Biotech Index (NBI) outperform the broader market in the last three months …

Indices, IPOs, and New Drug Approvals – Update July 6th 2012

1. Stock Performance. The Nasdaq Biotech Index (NBI) continued on its path of outperforming the …

Indices, IPOs, and New Drug Approvals - Update April 3rd 2012

1. Stock Performance. The Nasdaq Biotech Index (NBI) continued to outperform in March, maintaining its …

Sizing up the NBI in 2011

How did the Nasdaq Biotechnology Index (NBI) perform in 2011 relative to other sectors? Second …

Nasdaq Biotech Index re-ranking for next Monday

Twice a year, in May and November, the NASDAQ OMX Group re-ranks the closely watched …

Biotech Sector Performance Update 1H 2010

In my last update back in April, the broadest Biotech index (the 125 company Nasdaq …